Therapeutic Response

c-Met >= 50% status confers therapeutic sensitivity to Telisotuzumab Vedotin in patients with Lung Non-Squamous Non-Small Cell Carcinoma.

Statements

Source and description

Emrelis (telisotuzumab vedotin-tllv) [package insert]. FDA. The U.S. Food and Drug Administration (FDA) granted accelerated approval to telisotuzumab vedotin, a c-Met-directed antibody and microtubule inhibitor conjugate, for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [>=50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).